Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240974 | 0.82 | SLC6A4 (0.48) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL8390910 | 0.81 | CYP2D6 (0.60) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL5837752 | 0.81 | SLC6A4 (0.83) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL10050765 | 0.81 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL10656350 | 0.80 | SLC6A4 (0.48) | SLC6A4HTR2AKCNH2SLC6A2PDE2A | |
| SCHEMBL1259906 | 0.80 | CYP3A4 (0.55) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL29793859 | 0.79 | CYP3A4 (0.57) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL20509493 | 0.79 | CYP3A4 (0.57) | SLC6A4HTR2AKCNH2CYP3A4CYP2D6 | |
| SCHEMBL5436712 | 0.79 | SLC6A4 (0.43) | SLC6A4HTR2AKCNH2CYP3A4SLC6A2 | |
| SCHEMBL13020820 | 0.78 | SLC6A4 (0.44) | SLC6A4HTR2AKCNH2SLC6A2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | SLC6A4 134/4885HTR2A 192/4885KCNH2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.